Example: Heart Attack

Clinical Trials on Hurthle Cell Thyroid Cancer

Total 13 results

    • NCT02143726
      Active, not recruiting
      Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
      Conditions: Refractory Hurthle Cell Thyroid Cancer
    • NCT01100619
      Completed
      A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors
      Conditions: Papillary Thyroid Cancer; Follicular Thyroid Cancer; Huerthle Cell Thyroid Cancer; Renal Cell Carcinoma
    • NCT00001160
      Recruiting
      Studies on Tumors of the Thyroid
      Conditions: Hurthle Cell Thyroid Cancer; Tall Cell Variant Thyroid Cancer; Follicular Thyroid Cancer; Thyroid Cancer; Papillary Thyroid Cancer
    • NCT01441154
      Completed
      Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment
      Conditions: Malignant Struma Ovarii; Papillary Thyroid Cancer; Hurthle Cell Thyroid Cancer; Follicular Thyroid Cancer; Tall Cell Variant Thyroid Cancer
    • NCT01398085
      Active, not recruiting
      IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients
      Conditions: Thyroid Cancer
    • NCT00098813
      Completed
      Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine
      Conditions: Recurrent Thyroid Cancer; Stage IV Follicular Thyroid Cancer; Stage IV Papillary Thyroid Cancer
    • NCT00121628
      Completed
      A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer
      Conditions: Thyroid Cancer
    • NCT04544111
      Recruiting
      PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
      Conditions: Thyroid Cancer; Thyroid Cancer, Follicular; Papillary Thyroid Cancer; Follicular Thyroid Cancer; Hurthle Cell Tumor; Poorly Differentiated Thyroid Gland Carcinoma; Hurthle Cell Thyroid Neoplasia
    • NCT01208051
      Active, not recruiting
      Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer
      Conditions: Refractory Differentiated Thyroid Gland Carcinoma; Refractory Thyroid Gland Follicular Carcinoma; Refractory Thyroid Gland Hurthle Cell Carcinoma; Refractory Thyroid Gland Papillary Carcinoma; Unresectable Thyroid Gland Carcinoma
    • NCT03914300
      Recruiting
      Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
      Conditions: Differentiated Thyroid Gland Carcinoma; Follicular Variant Thyroid Gland Papillary Carcinoma; Poorly Differentiated Thyroid Gland Carcinoma; Refractory Differentiated Thyroid Gland Carcinoma; Refractory Thyroid Gland Carcinoma; Tall Cell Variant Thyroid Gland Papillary Carcinoma; Thyroid Gland Follicular Carcinoma; Thyroid Gland Hurthle Cell Carcinoma; Thyroid Gland Papillary Carcinoma
    • NCT00381641
      Active, not recruiting
      Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
      Conditions: Differentiated Thyroid Gland Carcinoma; Recurrent Thyroid Gland Carcinoma; Refractory Thyroid Gland Carcinoma; Stage III Thyroid Gland Follicular Carcinoma AJCC v7; Stage III Thyroid Gland Medullary Carcinoma AJCC v7; Stage IV Thyroid Gland Follicular Carcinoma AJCC v7; Stage IV Thyroid Gland Medullary Carcinoma AJCC v7; Stage IV Thyroid Gland Papillary Carcinoma AJCC v7; Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7; Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7; Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7; Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7; Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7; Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7; Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7; Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7; Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7; Thyroid Gland Hurthle Cell Carcinoma; Unresectable Thyroid Gland Carcinoma
    • NCT02973997
      Active, not recruiting
      Lenvatinib and Pembrolizumab in DTC
      Conditions: Columnar Cell Variant Thyroid Gland Papillary Carcinoma; Follicular Variant Thyroid Gland Papillary Carcinoma; Poorly Differentiated Thyroid Gland Carcinoma; Recurrent Thyroid Gland Carcinoma; Stage III Differentiated Thyroid Gland Carcinoma AJCC v7; Stage III Thyroid Gland Follicular Carcinoma AJCC v7; Stage III Thyroid Gland Papillary Carcinoma AJCC v7; Stage IV Thyroid Gland Follicular Carcinoma AJCC v7; Stage IV Thyroid Gland Papillary Carcinoma AJCC v7; Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7; Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7; Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7; Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7; Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7; Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7; Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7; Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7; Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7; Tall Cell Variant Thyroid Gland Papillary Carcinoma; Thyroid Gland Hurthle Cell Carcinoma
    • NCT01025453
      Completed
      Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
      Conditions: Thyroid Cancer
      Medical Conditions
      Sponsors and Collaborators
      Drug Interventions
      Conditions
      Rare Diseases
      Drug Interventions
      Dietary Supplements
      Sponsor/Collaborators
      Locations